Revisiting Survival in the Treatment of Spinal Metastases From Lung Cancer in the Modern Era of Immunotherapy and Molecular Targeted Treatment (2017-2022).

Spine (Phila Pa 1976) · Jul 15 2026 · Recent

Striano BM, Ferrone ML, Holly KE, Zheng C, Nguyen A, Macksood J, et al.

Department of Orthopaedic Surgery, Mass General Brigham, Harvard Medical School, MA

Orthopaedic Oncology Spine

SUMMARY — THE REDUCTIONSpinal metastases from lung cancer carry higher one-year mortality; surgical intervention and good nutritional status improve survival, while immunotherapy shows only short-term benefit.
Abstract, as published

OBJECTIVE: To assess survival among patients with spinal metastases from lung cancer treated over a time period that accounts for advances in immunotherapy and targeted treatments.

SUMMARY OF BACKGROUND DATA: The use of immunotherapy and targeted treatments has improved survival for patients with lung cancer, questioning whether secular trends have ushered in a new landscape in the field of spinal metastases.

MATERIALS AND METHODS: We identified patients who underwent operative or nonoperative treatment for spinal metastases (2017-2022). The primary outcome was one-year survival. We used multivariable logistic regression analysis to adjust for confounders, including all variables abstracted as covariates based on the conceptual model. We also assessed for interactions between lung cancer and surgical intervention and between surgical intervention and immunotherapy.

RESULTS: We included 997 patients, with 228 (22.9%) possessing a primary lung cancer diagnosis. At one year, lung cancer was significantly associated with the odds of mortality (OR: 2.01; 95% CI: 1.44-2.82). Surgical intervention (OR: 0.70; 95% CI: 0.53-0.92), serum albumin of 3.5 g/dL or greater (OR: 0.34; 95% CI: 0.24-0.47) and ambulatory status (OR: 0.47; 95% CI: 0.34-0.64) were all significantly associated with reduced likelihood of mortality. There was no significant association between immunotherapy and one-year survival (OR: 0.82; 95% CI: 0.61-1.11; P =0.19). At 30 days (OR: 0.55; 95% CI: 0.29-0.98) and 90 days (OR: 0.65; 95% CI: 0.45-0.93), immunotherapy was significantly associated with survival.

CONCLUSIONS: One-year survival in the cohort of patients with spinal metastases derived from lung cancer was significantly lower than that of metastases from other cancers. Surgical intervention did not mitigate this fact. Immunotherapy may exert an effect on near-term survival only. The signals for some of these temporal changes are robust enough to warrant consideration of their impact on traditional prognostic utilities in the future.

STUDY DESIGN: Retrospective cohort.

LEVEL OF EVIDENCE: Level III.

Read the article: PubMed · Publisher (DOI)

Featured in the 2026-07-22 issue.

← Musculoskeletal oncology and thermal ablation: the current an…Quality of Life Implications as a Consequence of Surgery: Lim… →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.